Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis – A non-infectious cause of breathlessness

The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a s...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis and related disorders Vol. 22; pp. 139 - 140
Main Authors Whiteside, D., Barth, S., Datta, A., Trip, S.A.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.05.2018
Subjects
Alemtuzumab
Interstitial
Lung diseases
Multiple sclerosis
Multiple sclerosis
Interstitial
Alemtuzumab
Lung diseases
Online AccessGet full text

Cover

More Information
Summary:The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab. •Pneumonitis can occur following treatment with the monoclonal antibody alemtuzumab in a patient with multiple sclerosis.•In a patient presenting with breathlessness post alemtuzumab infusion a non-infectious cause needs to be considered.•Pneumonitis secondary to alemtuzumab can potentially be managed with oral steroids alone.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2018.04.002